GILD
NASDAQ
$133.21
Gilead Sciences Inc (GILD)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Buy
Target: $158.30 (+18.83%)
Market Cap
$164B
PEG Ratio
0.32
EPS 5Y CAGR
+98.59%
Profit Margin
29%
Price Chart
Valuation
Market Cap$164B
P/E17.75
Forward P/E15.22
PEG0.32
P/S5.43
P/B6.94
Profitability
Total Revenue (TTM)$30B
Gross Profit (TTM)$24B
EBITDA$11B
Profit Margin29%
Operating Margin37.2%
EPS$7.42
Financial Health
Debt-to-Equity94.3%
Free Cash Flow Yield6.25%
Dividend Yield2.34%
Growth & Risk
EPS 5Y CAGR+98.59%
Revenue 5Y CAGR+3.07%
FCF 5Y CAGR+3.30%
Dividends 5Y CAGR+2.98%
Beta (5Y)0.35
Sharpe Ratio0.84